Under the terms of the agreement, Nutrilenea has been given the rights to use OptiBiotix’s cholesterol and blood pressure-reducing LPLDL product in a food supplement for the reduction of high blood pressure (hypertension).
Nutrilinea will cover the cost of all product development, manufacturing and human studies in return for 12 months exclusivity for the European market, excluding the UK - ProBiotix has exclusivity for the UK and all other markets outside Europe.
Nutrilinea currently produces the OptiBiotix’s CholBiome, CholBiomex3 and SlimBiome Medical products and has technology that enables the production of multilayer tablets used in CholBiomex3 that will also be used for this new product.
"We are delighted to announce this deal with Nutrilinea who are covering the cost of product development, manufacturing and human studies, for a food supplement to reduce blood pressure,” said Dr Luis Gosalbez, the business development director at OptiBiotix.
“This broadens the use of LPLDL beyond cholesterol reduction and creates new market opportunities in the field of cardiovascular health. Hypertension is a global health issue which is on the rise where there are very few active ingredients or supplements proven to lower blood pressure in humans. The development of a hypertension product containing LPLDL has the potential to address a large global market of unmet clinical need," he added.